| | Over a decade in the making, CAR T-Cell Therapy has proven to be one of the more innovative and promising treatments in oncology. Learn more about what companies should consider when it comes to this cutting edge treatment from a free white paper by TD2. |
AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test FDA demands more data from Solid Bio to lift gene therapy hold Sponsored: FROM CHOLERA TO COVID-19: How integrated data visualizations inform decisions and impact actions MBX Biosciences debuts with $35M to advance treatments for rare endocrine diseases TCR2's T-cell therapy curbs solid tumors in early phase 1 readout FDA authorizes first COVID-19 test for screening people without symptoms The top 20 drugs by global sales in 2019 Featured Story | By Nick Paul Taylor AstraZeneca is set to pay Daiichi Sankyo $1 billion to co-develop the antibody-drug conjugate (ADC) DS-1062 outside of Japan. The deal, which features a further $5 billion in milestones, represents a big bet on a solid tumor drug that hits the same target as Immunomedics’ approved ADC Trodelvy. read more |
| |
|---|
|
Top Stories By Ben Adams Moderna has been handed an extra $472 million to run its phase 3 COVID-19 vaccine test. read more By Nick Paul Taylor The FDA has maintained a clinical hold on a phase 1/2 clinical trial of Solid Biosciences’ gene therapy treatment for Duchenne muscular dystrophy (DMD). Solid Bio will need to submit more information on subjects including the total viral load per patient to persuade the FDA to lift the clinical hold. read more Sponsored by PerkinElmer, Inc How integrated data visualizations inform decisions and impact actions. Data visualization was first used to recognize disease patterns in the 1854 London cholera outbreak. It is even more essential today. read more By Amirah Al Idrus Richard DiMarchi, Ph.D., ex-Eli Lilly executive and serial entrepreneur, is getting the band back together. Along with former colleagues and a group of familiar investors, he’s setting up MBX Biosciences, a new biotech focused on rare endocrine diseases. It starts out with $34.6 million in funding from the likes of Frazier Healthcare Partners, OrbiMed and New Enterprise Associates. read more By Amirah Al Idrus TCR2 Therapeutics' lead program shrank tumors in five patients with mesothelin-expressing cancers, with two patients seeing enough shrinkage to be considered partial responders. Of the five patients, one had ovarian cancer and four had mesothelioma, a cancer of the mesothelium, the thin tissue that lines the lung, chest wall and abdomen. read more By Conor Hale The FDA has authorized LabCorp's test for broad-based screening—including for people who have not shown any symptoms and those that do not suspect they have come into contact with someone with the disease. read more By Kyle Blankenship For any drugmaker, taking a med to the billion-dollar sales mark—also known as a blockbuster—is a massive achievement in its own right. But for the pharmaceutical industry's bestselling drugs, some of which are blockbusters many times over, the bar is set much higher. read more Resources Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. The Bioprocessing Summit Virtual – Solving Today’s Challenges, Leading to Tomorrow’s Advances August 24-28, 2020 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 